AnnJi Pharmaceutical

AnnJi Pharmaceutical Taiwan’s Leading New Drug Developer In Dermatology, Neurology, and Rare Diseases

🌟 持續深耕人才培育,為下世代生醫產業注入新血!昨天,安基非常榮幸能參與台大藥學系的實習招募說明會!這已經是我們連續第五年回到校園,與這群優秀的生醫新秀們互動交流。在藥學系學生的職涯地圖中,除了臨床藥師或外商藥廠,安基想提供大家另一個充滿挑...
19/03/2026

🌟 持續深耕人才培育,為下世代生醫產業注入新血!
昨天,安基非常榮幸能參與台大藥學系的實習招募說明會!這已經是我們連續第五年回到校園,與這群優秀的生醫新秀們互動交流。

在藥學系學生的職涯地圖中,除了臨床藥師或外商藥廠,安基想提供大家另一個充滿挑戰與成就感的選項:在台灣本土藥廠投身「原創」新藥研發!

我們深信,台灣具備頂尖的科研實力。安基的實習計畫致力於提供第一手的業界經驗,陪伴學生們將學理知識與產業實務接軌。這不只是實習,更是學生從學術殿堂跨足生技產業的重要基石,能賦予大家真正的國際視野,看見台灣研發的新藥如何走向世界舞台。
透過投資這群未來的生醫領袖,我們不只是在打造人才庫,更是要讓台灣的研發實力向下紮根。讓我們攜手並進,共同形塑產業未來,將台灣的新藥研發突破推向國際! 🌍

非常期待很快能見到下一批優秀的實習生加入安基團隊!

#新藥研發 #人才培育 #實習計畫 #生技新血 #國際視野

< A Letter from the CEO: AnnJi’s Steadfast Commitment to the SBMA Community>To our SBMA patients, caregivers, and advoca...
06/01/2026

< A Letter from the CEO: AnnJi’s Steadfast Commitment to the SBMA Community>

To our SBMA patients, caregivers, and advocates:
In a heartfelt new letter from our CEO, Dr. Wendy Huang, AnnJi shares an update on our ongoing progress—and our unwavering commitment to turning scientific research into real, tangible hope.

The road to developing treatments for rare diseases can be long, but we are moving forward with sincerity, urgency, and transparency every step of the way.

We invite you to read this message of commitment to the SBMA community as we prepare together for the next important milestone of AJ201.

Full letter available on our website: https://www.ajpharm.com/news/index/2/213?lang=en

✨ 歲末感謝,溫暖相伴 ✨在這一年即將畫下句點之際,我們由衷感謝每一位合作夥伴的信任與支持,因為有你們一路同行,安基才能持續推動新藥創新,為病患帶來更多希望💙展望新的一年,我們期待與大家繼續攜手合作,勇於創新,為更多生命創造改變。祝福大家佳...
23/12/2025

✨ 歲末感謝,溫暖相伴 ✨

在這一年即將畫下句點之際,我們由衷感謝每一位合作夥伴的信任與支持,因為有你們一路同行,安基才能持續推動新藥創新,為病患帶來更多希望💙
展望新的一年,我們期待與大家繼續攜手合作,勇於創新,為更多生命創造改變。
祝福大家佳節愉快,新的一年充滿希望與可能🎉✨

#佳節祝福 #攜手同行 #新藥研發 #安基生技 #合作夥伴 #帶來希望

🌟 Hope for the Kennedy’s Disease Community 🌟At the 2025 WMS Congress, Dr. Tahseen Mozaffar, an investigator of the study...
02/12/2025

🌟 Hope for the Kennedy’s Disease Community 🌟
At the 2025 WMS Congress, Dr. Tahseen Mozaffar, an investigator of the study, shared encouraging Phase 2a clinical results for AJ201, AnnJi’s first-in-class therapy for Kennedy’s disease (SBMA).

We’re grateful to the global SBMA community and partners like Kennedy's Disease UK for helping raise awareness and driving progress. 💙
Momentum is growing — and so is hope.

🌟 Breakthrough for the Kennedy’s Disease Community!

At the 2025 World Muscle Society Congress, researchers shared promising Phase 2a results for AJ201, a potential first-in-decades disease-modifying treatment for Kennedy’s Disease (SBMA).

Read the press release on PR Newswire: https://www.prnewswire.com/news-releases/annji-showcases-clinical-breakthrough-of-aj201-at-wms-2025-302581832.html

Hope is growing - and so is the momentum for change. 💙

Address

16F-6, No.508, Zhongxiao East Rd., Nangang District, Taipei City, Taiwan
Taipei City
115

Opening Hours

Monday 09:00 - 18:00
Tuesday 09:00 - 18:00
Wednesday 09:00 - 18:00
Thursday 09:00 - 18:00
Friday 09:00 - 18:00

Telephone

+886223652677

Alerts

Be the first to know and let us send you an email when AnnJi Pharmaceutical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to AnnJi Pharmaceutical:

Shortcuts

Share